US 8853277
Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)
granted A61KA61K31/40A61K31/421
Quick answer
US patent 8853277 (Nitroxide therapy for the treatment of von Hippel—Lindau disease (VHL) and renal clear cell carcinoma (RCC)) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- The United States of America, as represented by the Secretary, Department of Health and Human Services
- Grant date
- Tue Oct 07 2014 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 02 2034 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 36
- CPC classes
- A61K, A61K31/40, A61K31/421, A61K31/445, A61P